Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020, 164(2):203-208 | DOI: 10.5507/bp.2019.015

Serum sphingosine negatively correlates with albumin predicting the risk of hepatocellular carcinoma

Kai Huanga, Wanlian Lia, Juan Xiaob, Diteng Luoa, Junfei Jina,b,c
a Laboratory of Hepatobiliary and Pancreatic Surgery, the Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, People's Republic of China
b China-USA Lipids in Health and Disease Research Center, Guilin Medical University, Guilin, 541001, Guangxi, People's Republic of China
c Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Guilin, 541001, Guangxi, People's Republic of China

Background: The roles of sphingosine in various cancers have not been fully investigated. Our aim was to identify the relationship between serum sphingosine and the risk of hepatocellular carcinoma (HCC).

Methods: Serum sphingosine in 34 normal people and 73 HCC patients were reviewed retrospectively. Receiver operating characteristic curve analysis was performed to determine the cut-off values of sphingosine in the serum. Chi-square test, t test and regression analysis were used to test the association between serum sphingosine and individual clinicopathologic parameters.

Results: Serum sphingosine was higher in HCC patients (155.91±331.5 ng/mL) with normal persons as the control (30.92±29.4 ng/mL). The sphingosine threshold according to ROC curve was set at 22.5 ng/mL with a sensitivity of 74%, and a specificity of 55.9%. Meanwhile, sphingosine in HCC patients with abnormal albumin was significantly higher than that in patients with normal albumin (t=2.452, P=0.019). When HCC patients were divided into two groups serum sphingosine was negatively associated with albumin in HCC patients (χ2=4.469, P=0.035). Moreover, the logistic regression analysis showed that large tumor size (P=0.018, OR=0.13) and a low albumin (P=0.005, OR=8.856) were two independent risk factors for serum sphingosine upregulation. High AFP coupled with high serum sphingosine, high sphingosine and high AFP respectively were found in 91.2%, 75.4%, 73% of the HCC patients.

Conclusions: These results suggest that serum sphingosine could be treated as a marker for the risk of HCC. AFP and sphingosine in the serum could be used together for HCC diagnosis.

Keywords: serum sphingolipid, HCC, albumin

Received: December 3, 2018; Revised: April 4, 2019; Accepted: April 4, 2019; Prepublished online: April 17, 2019; Published: June 18, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Huang, K., Li, W., Xiao, J., Luo, D., & Jin, J. (2020). Serum sphingosine negatively correlates with albumin predicting the risk of hepatocellular carcinoma. Biomedical papers, 164(2), 203-208. doi: 10.5507/bp.2019.015
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19(2):223-38. Go to original source... Go to PubMed...
    2. Du F, Chirovsky D, Xiong XJ, Li JH, Qiao YL, Zhang YJ, Zhang J. Inpatient Treatment Patterns and Health Care Expenditures for Hepatocellular Carcinoma among the Population with Urban Basic Health Insurance in China. Value Health Reg Issues 2015;6:132-40. Go to original source... Go to PubMed...
    3. Qiu F, Qiu F, Liu L, Liu J, Xu J, Huang X. The Role of Dermcidin in the Diagnosis and Staging of Hepatocellular Carcinoma. Genet Test Mol Biomarkers 2018;22(4):218-23. Go to original source... Go to PubMed...
    4. Nagao Y, Sata M. Serum albumin and mortality risk in a hyperendemic area of HCV infection in Japan. Virol J 2010;7:375. Go to original source... Go to PubMed...
    5. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28(10):1660-5. Go to original source... Go to PubMed...
    6. Eggert T, Greten TF. Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma. Digestion 2017;96(1):1-4. Go to original source... Go to PubMed...
    7. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9(2):139-50. Go to original source... Go to PubMed...
    8. Hannun YA, Bell RM. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 1987;235(4789):670-4. Go to original source... Go to PubMed...
    9. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4(8):604-16. Go to original source... Go to PubMed...
    10. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998;279(5356):1552-5. Go to original source... Go to PubMed...
    11. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010;10(7):489-503. Go to original source... Go to PubMed...
    12. Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature 2014;510(7503):58-67. Go to original source... Go to PubMed...
    13. Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhaberle E, Kaufmann M, Ackermann H, Lotsch J, Schmidt H, Geisslinger G, Grosch S. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009;30(5):745-52. Go to original source... Go to PubMed...
    14. Thomas RJ, Oleinik N, Panneer Selvam S, Vaena SG, Dany M, Nganga RN, Depalma R, Baron KD, Kim J, Szulc ZM, Ogretmen B. HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy. 2017;9(8):1030-51. Go to original source... Go to PubMed...
    15. Teng M, Pirrie S, Ward DG, Assi LK, Hughes RG, Stocken D, Johnson PJ. Diagnostic and mechanistic implications of serum free light chains, albumin and alpha-fetoprotein in hepatocellular carcinoma. Br J Cancer 2014;110(9):2277-82. Go to original source... Go to PubMed...
    16. Song JH, Jeong BK, Choi HS, Jeong H, Lee YH, Kim HJ, Kim TH, Jung WT, Lee OJ, Jang HS, Choi BO, Kang KM. Defining Radiation-Induced Hepatic Toxicity in Hepatocellular Carcinoma Patients Treated with Stereotactic Body Radiotherapy. J Cancer 2017;8(19):4155-61. Go to original source... Go to PubMed...
    17. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005;7(1):26-34. Go to original source... Go to PubMed...
    18. Li Y, Li DJ, Chen J, Liu W, Li JW, Jiang P, Zhao X, Guo F, Li XW, Wang SG. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma. Asian Pac J Cancer Prev 2015;16(8):3451-5. Go to original source... Go to PubMed...
    19. Bonis PA, Tong MJ, Blatt LM, Conrad A, Griffith JL. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol 1999;94(6):1605-12. Go to original source... Go to PubMed...
    20. Mao Z, Sun W, Xu R, Novgorodov S, Szulc ZM, Bielawski J, Obeid LM, Mao C. Alkaline ceramidase 2 (ACER2) and its product dihydrosphingosine mediate the cytotoxicity of N-(4-hydroxyphenyl)retinamide in tumor cells. J Biol Chem 2010;285(38):29078-90. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content